Business Context and Reporting Period
Company: Calumet, Inc. (CLMT)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2025
Overview: Calumet manufactures, formulates, and markets specialty branded products and renewable fuels. Operations are managed through four segments: Specialty Products and Solutions, Montana/Renewables, Performance Brands, and Corporate. The company completed a C-Corp conversion in July 2024.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Sales | $993.9 million | $1,005.8 million |
| Gross Profit (Loss) | $(81.4) million | $78.5 million |
| Operating Income (Loss) | $(48.7) million | $36.3 million |
| Net Loss | $(162.0) million | $(41.6) million |
| Adjusted EBITDA | $38.1 million | $28.1 million |
| Cash Used in Operating Activities | $(110.6) million | $(94.0) million |
| Total Debt (Long-term + Current) | $2,326.1 million | $2,100.2 million |
| Total Liquidity | $542.7 million | $211.8 million |
Note: Liquidity includes $123.4 million unrestricted cash, $80.0 million restricted cash, and $339.3 million available under credit facilities.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased to $162.0 million from $41.6 million, driven primarily by a $117.2 million non-cash RINs expense, $47.6 million in debt extinguishment costs, and a $62.2 million gain on the sale of the Royal Purple industrial business.
- Gross Margin Compression: The company reported a gross loss of $81.4 million compared to a gross profit of $78.5 million in Q1 2024. This was largely due to mark-to-market adjustments on Renewable Identification Numbers (RINs) totaling $86.8 million in expense, compared to a $71.1 million benefit in the prior year.
- Debt Restructuring: The company secured a $1.44 billion DOE Loan facility, with the first tranche of $781.8 million funded in February 2025. Proceeds were used to repay $368.1 million in MRL asset financing arrangements and other term loans, resulting in significant debt extinguishment costs.
- Asset Sale: The company sold assets related to the industrial portion of its Royal Purple business for net proceeds of $95.4 million, recording a $62.2 million gain.
Guidance, Outlook, and Risks
- Outlook: Management expects the current margin environment for specialty and fuel products to continue into Q2 2025. Demand remains strong across the enterprise. The Montana Renewables facility has returned to expected throughput following a Q4 turnaround.
- Capital Expenditures: Forecasted total capital expenditures for 2025 are $60 million to $90 million, excluding the MaxSAF project. MaxSAF funding is expected to come from MRL cash flows and the DOE Facility.
- RINs and Regulatory Risk: The company faces significant exposure to RINs pricing and regulatory changes. Pending litigation regarding Small Refinery Exemptions (SREs) for 2018-2023 remains a critical contingency. A $1.00 increase in RIN prices could negatively impact net income by approximately $65.0 million annually.
- DOE Loan Milestones: The second tranche of the DOE Loan ($658.0 million) is subject to achieving specific project milestones for the MaxSAF expansion. Failure to meet these could impact funding availability.
Investor Verification Checklist
- RINs Obligation Status: Verify the current status of EPA Small Refinery Exemption (SRE) petitions for 2018-2023 and the impact of the Supreme Court oral arguments heard in March 2025.
- DOE Loan Covenants: Review the specific milestones required to draw the second tranche of the $1.44 billion DOE Loan and the risk of amortization events.
- Debt Extinguishment Costs: Confirm the one-time nature of the $47.6 million debt extinguishment costs and the long-term interest savings from refinancing MRL debt with the DOE Loan.
- Segment Performance: Analyze the divergence between GAAP gross loss and Adjusted EBITDA, specifically the impact of non-cash RINs mark-to-market adjustments on reported profitability.
- Liquidity Position: Assess the sustainability of the $542.7 million liquidity position given the $110.6 million cash burn from operations in Q1 2025.